Background: Guillain-Barré Syndrome (GBS) is an acute paralytic polyneuropathy that may progress to respiratory failure and death, with a global prevalence of approximately 1.9 per 100,000 population annually. Two main immunotherapy modalities are recommended as first-line treatments, namely intravenous immunoglobulin (IVIg) and plasmapheresis. Although both therapies have shown comparable eff…